Crohn's Disease

Crohn’s disease previously unresponsive to conventional and biologic therapies showed response to Skyrizi, achieving clinical remission in more than a third of patients regardless of dosing, according to a presentation at Digestive Diseases Week.

Increased consumption of processed foods correlated with the development of inflammatory bowel disease, according to a presentation at Digestive Disease Week.

In this video exclusive, Benjamin Click, MD, from Cleveland Clinic, discussed the accuracy of imaging for the detection of postoperative Crohn’s disease recurrence.

Rising rates of ultra-processed food consumption correlated with an increased risk for Crohn’s disease, according to a presentation at Digestive Disease Week.

Alcohol use disorder correlated with a higher risk for in-hospital mortality among patients with inflammatory bowel disease, according to a presentation at Digestive Disease Week.

Crohn’s disease and ulcerative colitis disproportionately affected non-Hispanic white patients, according to research presented at Digestive Disease Week.

In an exclusive video with Healio Gastroenterology, Benjamin Click, MD, Cleveland Clinic, spoke about the safety and efficacy of Stelara and Entyvio in elderly patients with Crohn’s disease.

Patients with cirrhosis had a higher abundance of beta-lactamase, vancomycin and quinolone genes in their gut microbiota compared with patients with inflammatory bowel disease, chronic kidney disease and diabetes, according to a presentation from Digestive Diseases Week.

Proactive therapeutic drug monitoring vs. standard therapy did not significantly improve clinical remission rates over 30 weeks in patients with immune-mediated inflammatory diseases initiating Remicade therapy, according to study results.

Serum Leucine-rich alpha-2 glycoprotein was a useful biomarker of endoscopic activity in patients with Crohn’s disease and ulcerative colitis taking Humira, according to a study published in Journal of Gastroenterology.